Exploring Three High Growth Tech Stocks In The United States

The market has been flat over the last week but is up 23% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks that demonstrate strong potential and align well with these positive trends can be a strategic move for investors.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
TG Therapeutics	28.62%	43.05%	★★★★★★
Sarepta Therapeutics	24.22%	44.94%	★★★★★★
Ardelyx	27.44%	65.50%	★★★★★★
Super Micro Computer	20.76%	28.05%	★★★★★★
Iris Energy	69.80%	125.09%	★★★★★★
G1 Therapeutics	27.57%	57.75%	★★★★★★
Invivyd	42.85%	71.50%	★★★★★★
Amicus Therapeutics	20.45%	61.85%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Exact Sciences (NasdaqCM:EXAS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally, with a market cap of $11.06 billion.

Operations: The company's primary revenue stream comes from its biotechnology segment, generating $2.61 billion. Exact Sciences focuses on cancer screening and diagnostic tests across various markets.

Exact Sciences, a prominent player in cancer diagnostics, has reported significant strides with its Multi-Cancer Early Detection (MCED) Falcon Registry study. The company's Q2 2024 earnings showed a notable improvement, with sales rising to $699.26 million from $622.09 million the previous year and net loss narrowing to $15.81 million from $81.03 million. With R&D expenses focused on innovative solutions like the MCED test and strategic partnerships such as TwinStrand Biosciences' licensing agreement, Exact Sciences is poised for future growth in precision oncology and cancer screening markets.

• Click here to discover the nuances of Exact Sciences with our detailed analytical health report.

• Examine Exact Sciences' past performance report to understand how it has performed in the past.

ExlService Holdings (NasdaqGS:EXLS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: ExlService Holdings, Inc. operates as a data analytics and digital operations solutions company in the United States and internationally, with a market cap of approximately $5.87 billion.

Operations: ExlService Holdings generates revenue through four main segments: Analytics ($749.61 million), Insurance ($569.90 million), Healthcare ($106.48 million), and Emerging Business ($283.91 million).

ExlService Holdings has shown robust growth with earnings expected to rise 16% annually, outpacing the US market's 15.2%. The company's revenue is forecasted to grow at an 11.3% rate per year, surpassing the broader market's 8.8%. Notably, ExlService has repurchased $133.82 million worth of shares in recent months and raised its revenue guidance for 2024 to $1.805-$1.830 billion, reflecting a year-over-year growth of up to 12%.

• Take a closer look at ExlService Holdings' potential here in our health report.

• Evaluate ExlService Holdings' historical performance by accessing our past performance report.

Novanta (NasdaqGS:NOVT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Novanta Inc., along with its subsidiaries, offers precision medicine and manufacturing, medical solutions, and robotics and automation solutions globally, with a market cap of $6.55 billion.

Operations: Novanta generates revenue primarily from three segments: Medical Solutions ($371.24 million), Robotics and Automation ($260.32 million), and Precision Medicine and Manufacturing ($268.30 million). The company operates internationally, focusing on advanced technology solutions for various industries.

Novanta's revenue is projected to grow at 11.6% annually, outpacing the broader US market's 8.8%. Despite a recent earnings dip of 19.1%, future earnings are expected to rise significantly by 35.5% per year, reflecting strong growth potential in the tech sector. The company has invested substantially in R&D, with expenses reaching $42 million last year, emphasizing its commitment to innovation and maintaining a competitive edge within the industry.

• Get an in-depth perspective on Novanta's performance by reading our health report here.

• Explore historical data to track Novanta's performance over time in our Past section.

Summing It All Up

• Gain an insight into the universe of 249 US High Growth Tech and AI Stocks by clicking here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com